Topics

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

02:56 EDT 7 Jul 2019 | News-Medical.net

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC).

Original Article: Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

NEXT ARTICLE

More From BioPortfolio on "Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...